Developmental effects of von Hippel–Lindau gene deficiency
✍ Scribed by Alexander O. Vortmeyer; Quingyang Yuan; Youn-Soo Lee; Zhengping Zhuang; Edward H. Oldfield
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 931 KB
- Volume
- 55
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Mutations in the von Hippel-Lindau (VHL) gene are responsible for VHL disease, congenital polycythemia, and are found in many sporadic tumor types as well. Reports of VHL mutations are dispersed throughout original articles and databases that have not been recently updated. We compiled a comprehensi
## Abstract The Von Hippel‐Lindau __(VHL)__ gene product has a wide spectrum of tissue‐specific functions, and specific germline mutations are associated with clinical phenotypes in VHL disease. In particular, missense mutations are correlated with the susceptibility to pheochromocytomas. An associ
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene is responsible not only for VHL disease, but also for sporadic renal cell carcinoma and cerebellar haemangioblastoma. The distribution of VHL gene expression in the mouse embryo was recently studied by in situ hybridization, along wi
Von Hippel-Lindau disease is an autosomal dominantly inherited disorder characterised by the development of haemangioblastomas, renal carcinomas, retinal angiomata, pancreatic tumours, and phaeochromocytomas . The tumour suppressor gene responsible for VHL has been mapped to 3p25 and a partial sequ
The von Hippel-Lindau gene product (pVHL) interacts with and inhibits the cellular transcription factor elongin. However, the subcellular localization of pVHL has remained uncertain. Naturally occurring pVHL mutants which fail to interact with elongin have been described in patients with VHL disease